Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508227 | 0.90 | DPP4 (0.54) | DPP4CYP3A4 | |
| SCHEMBL5034640 | 0.89 | DPP4 (0.52) | DPP4CYP3A4 | |
| SCHEMBL3586029 | 0.85 | DPP4 (0.56) | DPP4CYP3A4 | |
| SCHEMBL3586023 | 0.84 | DPP4 (0.47) | DPP4CYP3A4 | |
| SCHEMBL6426896 | 0.84 | DPP4 (0.55) | DPP4CYP3A4 | |
| SCHEMBL6507784 | 0.81 | DPP4 (0.59) | DPP4 | |
| SCHEMBL6511158 | 0.80 | DPP4 (0.56) | DPP4 | |
| SCHEMBL3059451 | 0.76 | DPP4 (0.56) | DPP4CYP3A4 | |
| SCHEMBL13139857 | 0.76 | DPP4 (0.56) | DPP4CYP3A4 | |
| SCHEMBL3073729 | 0.73 | DPP4 (0.54) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007033265-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007033265-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060529-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DEVELOPMENT PARTNERS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060529-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DEVELOPMENT PARTNERS, LLC | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060529-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DPP7, DPP4, DPP3 | DPP4 2/4885CYP3A4 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.